A Path to Precision Metabolic Treatment in Breast Cancer: Riluzole, Glutamate Signaling, and Invasive Lobular Carcinoma

Affiliations

¹ Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
² Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN 55455, USA.

Comment

Matthew J Sikora et al. J Endocr Soc. 2023.

. 2023 Dec 26;8(2):bvad171.

doi: 10.1210/jendso/bvad171. eCollection 2024 Jan 5.

¹ Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
² Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN 55455, USA.

No abstract available

Keywords: PET/CT; anti-estrogen; breast cancer; glutamate; invasive lobular carcinoma; metabolism.

Comment on

Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer.
Olukoya AO, Stires H, Bahnassy S, Persaud S, Guerra Y, Ranjit S, Ma S, Cruz MI, Benitez C, Rozeboom AM, Ceuleers H, Berry DL, Jacobsen BM, Raj GV, Riggins RB. Olukoya AO, et al. J Endocr Soc. 2023 Sep 15;7(10):bvad117. doi: 10.1210/jendso/bvad117. eCollection 2023 Aug 28. J Endocr Soc. 2023. PMID: 37766843 Free PMC article.

A Stronger IMPACT on Career Development for Early- and Mid-career Faculty.
Gorelick DA, Gertz J, Basham KJ, Treviño LS. Gorelick DA, et al. J Endocr Soc. 2024 Nov 14;8(12):bvae191. doi: 10.1210/jendso/bvae191. eCollection 2024 Oct 29. J Endocr Soc. 2024. PMID: 39564580 Free PMC article.
Glutamate Transport Proteins and Metabolic Enzymes are Poor Prognostic Factors in Invasive Lobular Carcinoma.
Young TA, Bahnassy S, Abalum TC, Pope EA, Rivera AT, Fernandez AI, Olukoya AO, Mobin D, Ranjit S, Libbey NE, Persaud S, Rozeboom AM, Chaldekas K, Harris BT, Madak-Erdogan Z, Sottnik JL, Sikora MJ, Riggins RB. Young TA, et al. bioRxiv [Preprint]. 2024 Sep 29:2024.09.29.615681. doi: 10.1101/2024.09.29.615681. bioRxiv. 2024. PMID: 39464069 Free PMC article. Preprint.

1. Ulaner GA, Jhaveri K, Chandarlapaty S, et al. Head-to-head evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer. J Nucl Med. 2021;62(3):326‐331. - PMC - PubMed
1. Olukoya AO, Stires H, Bahnassy S, et al. Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer. J Endocr Soc. 2023;7(10):bvad117. - PMC - PubMed
1. Du T, Zhu L, Levine KM, et al. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Sci Rep. 2018;8(1):7205‐7205. - PMC - PubMed
1. Kim YH, Jung WH, Koo JS. Expression of metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma. Tumour Biol. 2014;35(10):10381‐10393. - PubMed
1. Du T, Sikora MJ, Levine KM, et al. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res. 2018;20(1):106. - PMC - PubMed